Allogeneic hematopoietic cell transplant for prolymphocytic leukemia

Area of Science:

• Hematology
• Oncology
• Transplant Medicine

Background:

• Prolymphocytic leukemia (PLL) has a poor prognosis, prompting investigation into advanced treatment options.
• Allogeneic hematopoietic cell transplant (HCT) is considered, but robust outcome data are lacking.

Purpose of the Study:

• To evaluate the efficacy and safety of allogeneic HCT in patients with prolymphocytic leukemia.
• To analyze survival outcomes and causes of mortality following HCT for PLL.

Main Methods:

• Retrospective review of the Center for International Blood and Marrow Transplant Research (CIBMTR) database.
• Analysis of data from 47 adult patients undergoing allogeneic HCT for PLL.

Main Results:

• One-year progression-free survival (PFS) was 33% (95% CI 20%-47%).
• Relapse or progression was the primary cause of death (49%).
• One-year treatment-related mortality (TRM) was 28%.

Conclusions:

• Allogeneic HCT is a viable consideration for PLL patients, given the limited therapeutic options.
• The study highlights significant risks of relapse and TRM, necessitating careful patient selection.
• Larger studies are required to identify prognostic factors and optimize HCT strategies for PLL.